TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M., van de Rijn, M., Jeffrey, S., et al. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.191367098 · Cited by 11,695 · see citing works

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Instability and decay of the primary structure of DNA

Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

Patterns of somatic mutation in human cancer genomes

Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062 · see citing works

Somatic mutations affect key pathways in lung adenocarcinoma

Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · see citing works

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · see citing works

Crypt stem cells as the cells-of-origin of intestinal cancer

Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. C. (2008) · Nature · doi:10.1038/nature07602 · Cited by 2,159 · see citing works

Definition of a consensus binding site for p53

El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · see citing works

Transcriptional control of human p53-regulated genes

Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · see citing works

Preferential Formation of Benzo[ <i>a</i> ]pyrene Adducts at Lung Cancer Mutational Hotspots in <i>P53</i>

Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650 · see citing works

Impact of mutant p53 functional properties on <i>TP53</i> mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · see citing works

Mutational hot spot in the p53 gene in human hepatocellular carcinomas

Hsu, I., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,533 · see citing works

Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa

Paillerets, B. B., Kew, M. C., Wands, J. R., & Öztürk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,433 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

A cancer family syndrome in twenty-four kindreds.

Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293 · see citing works

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L. A., Ploner, A., Yudi Pawitan, Y., Hall, P. N., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,269 · see citing works

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

Dumont, P., Leu, J. I.-J., Pietra, A. D., George, D. L., & Murphy, M. E. (2003) · Nature Genetics · doi:10.1038/ng1093 · Cited by 1,269 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · see citing works

The IARC TP53 database: new online mutation analysis and recommendations to users

Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248 · see citing works

p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53

Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00073-8 · Cited by 1,162 · see citing works

Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers

Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N. Y., Hecht, S. S., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205803 · Cited by 1,114 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 980 · see citing works

Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer

Storey, A., Thomas, M., Kalita, A., Harwood, C. A., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., & Banks, L. (1998) · Nature · doi:10.1038/30400 · Cited by 971 · see citing works

Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

Kato, S., Han, S., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 877 · see citing works

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 749 · see citing works

Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically

Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., & Matlashewski, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1092 · Cited by 700 · see citing works

TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 623 · see citing works

Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations

Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607 · see citing works

Aristolochic acid and the etiology of endemic (Balkan) nephropathy

Grollman, A. P., Shibutani, S., Moriya, M., Miller, F. W., Wu, L., Moll, U. M., Suzuki, N., Fernandes, A., Rosenquist, T. A., Medverec, Z., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701248104 · Cited by 603 · see citing works

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J. C. S., Klaar, S., Eyfjord, J. E., Theillet, C. G., Rodríguez, C., Lidereau, R., Bièche, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 590 · see citing works

An inherited <i>p53</i> mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma

Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541 · see citing works

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511 · see citing works

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. L., & Eeles, R. A. (2003) · PubMed · Cited by 480 · see citing works

Relative frequency and morphology of cancers in carriers of germline TP53 mutations

Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467 · see citing works

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

Bergh, J. C. S., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 459 · see citing works

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445 · see citing works

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 442 · see citing works

Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 435 · see citing works

p53 polymorphic variants at codon 72 exert different effects on cell cycle progression

Pim, D., & Banks, L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11548 · Cited by 411 · see citing works

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408 · see citing works

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 389 · see citing works

Is p53 Polymorphism Maintained by Natural Selection?

Beckman, G., Birgander, R., lander, A. S. A., Saha, N., Holmberg, P., Kivel&auml;, A., & Beckman, L. E. (1994) · Human Heredity · doi:10.1159/000154228 · Cited by 362 · see citing works

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 354 · see citing works

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer

Stephens, P., Edkins, S., Davies, H. R., Greenman, C., Cox, C., Hunter, C., Bignell, G. R., Teague, J. W., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 333 · see citing works

TP53 mutations in human skin cancers

Giglia‐Mari, G., & Sarasin, A. R. (2003) · Human Mutation · doi:10.1002/humu.10179 · Cited by 293 · see citing works

A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer

DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B. B., Ribeiro, R. C., Zambetti, G. P., & Kriwacki, R. W. (2001) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 293 · see citing works

TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer

Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen‐Dale, A., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291 · see citing works

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner

Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0180 · Cited by 287 · see citing works

p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity

Wu, X. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.9.681 · Cited by 249 · see citing works

Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs

Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247 · see citing works

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

Sullivan, A., Syed, N., Gasco, M., Bergamaschi, D., Trigiante, G., Attard, M., Hiller, L., Farrell, P. J., Smith, P., Lü, X., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207428 · Cited by 247 · see citing works

TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.

Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243 · see citing works

Screening patients for heterozygous p53 mutations using a functional assay in yeast

Ishioka, C., Frébourg, T., Yan, Y.-X., Vidal, M., Friend, S. H., Schmidt, S., & Iggo, R. D. (1993) · Nature Genetics · doi:10.1038/ng1093-124 · Cited by 243 · see citing works

Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.

Ory, K., Legros, Y., Auguin, C., & Soussi, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06656.x · Cited by 229 · see citing works

The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families

Achatz, M. I., Olivier, M., Calvez‐Kelm, F. L., Martel‐Planche, G., Lopes, A., Rossi, B. M., Ashton‐Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 218 · see citing works

A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA

Gemignani, F., Moreno, V. R., Landi, S., Moullan, N., Chabrier, A., Gutiérrez‐Enríquez, S., Hall, J. A., Guinó, E., Peinado, M. A., Capellá, G., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207305 · Cited by 217 · see citing works

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome

Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugières, L., Chompret, A., Paillerets, B. B., Stoppa‐Lyonnet, D., Bonaïti‐Pellié, C., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037952 · Cited by 216 · see citing works

Germline mutations in the TP53 gene.

Eeles, R. A. (1995) · PubMed · Cited by 213 · see citing works

Characterization of genome-wide p53-binding sites upon stress response

Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J. J., Akkers, R. C., Denissov, S., Stunnenberg, H. G., & Lohrum, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn232 · Cited by 211 · see citing works

The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.

Langerød, A., Bukholm, I., Bregård, A., Lønning, P. E., Andersen, T. I., Rognum, T. O., Meling, G. I., Lothe, R. A., & Børresen‐Dale, A. (2002) · PubMed · Cited by 204 · see citing works

Methylation, mutation and cancer

Jones, P. A., Rideout, W. M., Shen, J., Spruck, C., & Tsai, Y. (1992) · BioEssays · doi:10.1002/bies.950140107 · Cited by 202 · see citing works

Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome

Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200 · see citing works

Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence

Inga, A., Storici, F., Darden, T. A., & Resnick, M. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8612-8625.2002 · Cited by 200 · see citing works

Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations

Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181 · see citing works

BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives

Lalloo, F. I., Varley, J. M., Moran, A., Ellis, D., O’Dair, L., Pharoah, P. D. P., Antoniou, A. C., Hartley, R., Shenton, A., Seal, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.032 · Cited by 175 · see citing works

Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer

Arlt, V. M., Stiborová, M., Brocke, J. V., Simões, M. L., Lord, G. M., Nortier, J., Hollstein, M., Phillips, D. H., & Schmeiser, H. H. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm082 · Cited by 173 · see citing works

Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients.

Bonafè, M., Ceccarelli, C., Farabegoli, F., Santini, D., Taffurelli, M., Barbi, C., Marzi, E., Trapassi, C., Storci, G., Olivieri, F., et al. (2003) · PubMed · Cited by 171 · see citing works

Dominant-negative p53 mutations selected in yeast hit cancer hot spots.

Brachmann, R. K., Vidal, M., & Boeke, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4091 · Cited by 159 · see citing works

TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis

Matakidou, A. (2003) · Mutagenesis · doi:10.1093/mutage/geg008 · Cited by 150 · see citing works

p53 Codon 72 Polymorphism and Cervical Neoplasia

Koushik, A., Platt, R. W., & Franco, E. L. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-083-3 · Cited by 146 · see citing works

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers

Dearth, L. R., Hua, Q., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 139 · see citing works

p53 polymorphism and risk of cervical cancer

Helland, Å., Langerød, A., Johnsen, H., Olsen, A. O., Skovlund, E., & Børresen‐Dale, A. (1998) · Nature · doi:10.1038/25034 · Cited by 134 · see citing works

Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool

Luo, J., Yang, Q., Tong, W., Hergenhahn, M., Wang, Z., & Hollstein, M. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204080 · Cited by 133 · see citing works

Trp53-dependent DNA-repair is affected by the codon 72 polymorphism

Siddique, M. M., & Sabapathy, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209405 · Cited by 130 · see citing works

Ser46 Phosphorylation Regulates p53-Dependent Apoptosis and Replicative Senescence

Feng, L., Hollstein, M., & Xu, Y. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3526 · Cited by 119 · see citing works

Prevalence of Early Onset Colorectal Cancer in 397 Patients With Classic Li–Fraumeni Syndrome

Wong, P., Verselis, S. J., Garber, J. E., Schneider, K. A., DiGianni, L. M., Stockwell, D. H., Li, F. P., & Syngal, S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.014 · Cited by 111 · see citing works

Molecular pathology in basal cell cancer with p53 as a genetic marker

Pontén, F., Berg, C., Ahmadian, A., Ren, Z.-P., Nistér, M., Lundeberg, J., Uhlén, M., & Pontén, J. (1997) · Oncogene · doi:10.1038/sj.onc.1201435 · Cited by 110 · see citing works

Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma

Jia, L., Liu, Y., Yi, X., Miron, A., Crum, C. P., Kong, B., & Zheng, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4837 · Cited by 110 · see citing works

TP53 Status and Response to Chemotherapy in Breast Cancer

Bertheau, P., Espié, M., Turpin, E., Lehmann‐Che, J., Plassa, L., Varna, M., Janin, A., & de Thé, H. (2008) · Pathobiology · doi:10.1159/000123851 · Cited by 108 · see citing works

Mechanisms for the involvement of DNA methylation in colon carcinogenesis.

Schmütte, C., Yang, A. S., Nguyen, T. T., Beart, R. W., & Jones, P. A. (1996) · PubMed · Cited by 104 · see citing works

p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

Xu, Y., Yao, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Lin, B., Lu, Y., & Xie, Y. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0507 · Cited by 102 · see citing works

The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer

Bull, S. B., Özçelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A. J., Pritchard, K. I., Tzontcheva, A., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.128 · Cited by 99 · see citing works

A nucleotide substitution model with nearest-neighbour interactions

Lunter, G. A., & Hein, J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth901 · Cited by 89 · see citing works

On the origin of G→T transversions in lung cancer

Pfeifer, G. P., & Hainaut, P. L. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00013-7 · Cited by 86 · see citing works

Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants

Tada, M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.515 · Cited by 86 · see citing works

p53 germline polymorphisms are associated with an increased risk for breast cancer in German women.

Wang‐Gohrke, S., Rebbeck, T. R., Besenfelder, W., Kreienberg, R., & Runnebaum, I. B. (1998) · PubMed · Cited by 84 · see citing works

Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments

de Fromentel, C. C., Gruel, N., Venot, C., Debüssche, L., Conseiller, E., Dureuil, C., Teillaud, J., Tocqué, B., & Bracco, L. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202338 · Cited by 83 · see citing works

TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy‐associated tumours

Nedelko, T., Arlt, V. M., Phillips, D. H., & Hollstein, M. C. (2008) · International Journal of Cancer · doi:10.1002/ijc.24006 · Cited by 82 · see citing works

Screening for TP53 rearrangements in families with the Li–Fraumeni syndrome reveals a complete deletion of the TP53 gene

Bougeard, G., Brugières, L., Chompret, A., Gesta, P., Charbonnier, F., Valent, A., Martin, C., Raux, G., Feunteun, J., Paillerets, B. B., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206155 · Cited by 80 · see citing works

Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer

Schneider‐Stock, R., Mawrin, C., Motsch, C., Boltze, C., Peters, B., Hartig, R., Buhtz, P., Giers, A., Rohrbeck, A., Freigang, B., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63211-7 · Cited by 76 · see citing works

Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs

Vikhanskaya, F., Siddique, M. M., Lee, M. K., Broggini, M., & Sabapathy, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1547 · Cited by 75 · see citing works

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival

Wang, Y., Helland, Å., Holm, R., Skomedal, H., Abeler, V. M., Danielsen, H. E., Tropé, C., Børresen-Dale, A.-L., & Kristensen, G. B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601537 · Cited by 68 · see citing works

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

Wang‐Gohrke, S., Weikel, W., Risch, H. A., Vesprini, D., Abrahamson, J., Lerman, C., Godwin, A. K., Moslehi, R., Olipade, O., Brunet, J., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690669 · Cited by 67 · see citing works

TP53 mutation, allelism and survival in non-small cell lung cancer

Nelson, H. H., Wilkojmen, M., Marsit, C. J., & Kelsey, K. T. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi125 · Cited by 66 · see citing works

A functional screen for germ line p53 mutations based on transcriptional activation.

Frébourg, T., Barbier, N., Kassel, J., Ng, Y. S., Beer‐Romero, P., & Friend, S. H. (1992) · PubMed · Cited by 64 · see citing works

TP53 polymorphism, HPV infection, and risk of cervical cancer.

Klug, S. J., Wilmotte, R., Santos, C., Almonte, M., Herrero, R., Guerrero, I., Caceres, E., Guimarães, D. P., Lenoir, G., Hainaut, P. L., et al. (2001) · PubMed · Cited by 55 · see citing works

Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53gene on survival in patients with advanced ovarian carcinoma

Wang, Y., Kringen, P., Kristensen, G. B., Holm, R., Baekelandt, M. M. O., Olivier, M., Skomedal, H., Hainaut, P. L., Trope, C. G., Abeler, V. M., et al. (2004) · Human Mutation · doi:10.1002/humu.20055 · Cited by 52 · see citing works

TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer

Santos, A. M., de Sousa, H. M. L., Portela, C. L., Pereira, D., Pinto, D., Catarino, R., Rodrigues, C., Araújo, A. P., Lopes, C., & Medeiros, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.176 · Cited by 51 · see citing works

MEF immortalization to investigate the ins and outs of mutagenesis

Brocke, J. V., Schmeiser, H. H., Reinbold, M., & Hollstein, M. C. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl101 · Cited by 48 · see citing works

Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72

Reinbold, M., Luo, J.-L., Nedelko, T., Jerchow, B., Murphy, M. E., Whibley, C. E., Wei, Q., & Hollstein, M. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210932 · Cited by 43 · see citing works

Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia

Kochethu, G., Delgado, J., Pepper, C. J., Starczynski, J., Hooper, L., Krishnan, S., Fegan, C., & Pratt, G. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.12.014 · Cited by 34 · see citing works

Molecular precursor lesions in oesophageal cancer.

Montesano, R., & Hainaut, P. L. (1998) · PubMed · Cited by 34 · see citing works

HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway

Pistritto, G., Puca, R., Nardinocchi, L., Sacchi, A., & D’Orazi, G. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402186 · Cited by 30 · see citing works

Clonal Analysis of Colorectal Tumors Using K-ras and p53 Gene Mutations as Markers

Dix, B. R., Robbins, P., Spagnolo, D. V., Padovan, G. L., House, A. K., & Iacopetta, B. J. (1995) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199512000-00006 · Cited by 29 · see citing works

Tumor Susceptibility and Apoptosis Defect in a Mouse Strain Expressing a Human p53 Transgene

Dudgeon, C., Kek, C., Demidov, O. N., Saito, S., Fernandes, K., Diot, A., Bourdon, J., Lane, D. P., Appella, E., Fornace, A. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2063 · Cited by 25 · see citing works

p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients

Wegman, P., Stål, O., Stenmark‐Askmalm, M., Nordenskjöld, B. A., Rutqvist, L., & Wingren, S. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000204997.84182.69 · Cited by 23 · see citing works

p53 Designer Genes for the Modern Mouse

Hergenhahn, M., Luo, J., & Hollstein, M. (2004) · Cell Cycle · doi:10.4161/cc.3.6.890 · Cited by 18 · see citing works

Arrayed Primer Extension Resequencing of Mutations in the TP53 Tumor Suppressor Gene: Comparison with Denaturing HPLC and Direct Sequencing

Calvez‐Kelm, F. L., Ahman, A., Tõnisson, N., Lambert, J., Temam, S., Brennan, P., Zaridze, D. G., Metspalu, A., & Hainaut, P. L. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.048348 · Cited by 18 · see citing works

A double germline mutations in the APC and p53 genes.

Zajac, Tomka, M., Ilenčíková, D., Májek, P., Števurková, V., & Kirchhoff, T. (2000) · PubMed · Cited by 10 · see citing works

Single-Nucleotide Polymorphisms in the p53 PathwayPreprint

Harris, S. L., Gil, G. A., Hu, W., Robins, H. S., Bond, E. E., Hirshfield, K. M., Feng, Z., YU, X., Teresky, A. K., Bond, G. L., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.024 · Cited by 9 · see citing works

Mouse models for generating P53 gene mutation spectra

Zielinski, B., Liu, Z., Hollstein, M. C., Hergenhahn, M., & Luo, J. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(02)00160-1 · Cited by 5 · see citing works

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer

Langerød, A., Zhao, H., Borgan, Ø., Jm, N., Hernandez‐Boussard, T., Bukholm, I., Kåresen, R., Børresen‐Dale, A., & Jeffrey, S. S. (2005) · Breast Cancer Research · doi:10.1186/bcr1174 · Cited by 3 · see citing works

Blinded by the Light: The Growing Complexity of p53

Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · see citing works

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works

Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 2,143 · see citing works

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,246 · see citing works

When mutants gain new powers: News from the mutant p53 field

Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · see citing works

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes &amp; Cancer · doi:10.1177/1947601911408889 · Cited by 1,033 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · see citing works

Mutant p53 drives invasion by promoting integrin recycling

Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796 · see citing works

Mutant p53 Gain-of-Function in CancerPreprint

Oren, M., & Rotter, V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753 · see citing works

The interplay between cell signalling and the mevalonate pathway in cancer

Mullen, P., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.76 · Cited by 697 · see citing works

The genetics of the p53 pathway, apoptosis and cancer therapy

Vázquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 674 · see citing works

Epidemiology of Glioblastoma Multiforme–Literature Review

Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska‐Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 662 · see citing works

The expanding universe of p53 targets

Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568 · see citing works

The chemistry, physiology and pathology of pH in cancer

Swietach, P., Vaughan‐Jones, R. D., Harris, A. L., & Hulı́ková, A. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0099 · Cited by 542 · see citing works

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death &amp; Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

Structure–function–rescue: the diverse nature of common p53 cancer mutants

Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 430 · see citing works

The role of mutant p53 in human cancer

Goh, A. M., Coffill, C. R., & Lane, D. P. (2010) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398 · see citing works

TP53 Mutations in Nonsmall Cell Lung Cancer

Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 392 · see citing works

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma

Long, J., Wang, A., Bai, Y., Lin, J., Yang, X., Wang, D., Yang, X., Jiang, Y., & Zhao, H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.022 · Cited by 380 · see citing works

p53 Acetylation: Regulation and Consequences

Reed, S. M., & Quelle, D. E. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 330 · see citing works

Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy

Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308 · see citing works

Emerging biomarkers in head and neck cancer in the era of genomics

Kang, H., Kiess, A. P., & Chung, C. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.192 · Cited by 311 · see citing works

Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

Salama, A. K. S., Li, S., Macrae, E. R., Park, J., Mitchell, E. P., Zwiebel, J. A., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00762 · Cited by 311 · see citing works

p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling

Kim, N. H., Kim, N.-G., Kim, N.-G., Lee, I., Choi, H.-S., Li, X.-Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001744 · Cited by 308 · see citing works

Nuclear Receptor Coregulators and Human Disease

Lonard, D. M., Lanz, R. B., & O’Malley, B. W. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0012 · Cited by 303 · see citing works

Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications

Otmani, K., & Lewalle, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708765 · Cited by 287 · see citing works

Mouse models of human AML accurately predict chemotherapy responsePreprint

Zuber, J. A., Radtke, I., Pardee, T. S., Zhao, Z., Rappaport, A., Luo, W., McCurrach, M. E., Yang, M., Dolan, M. E., Kogan, S. C., et al. (2009) · Genes & Development · doi:10.1101/gad.1771409 · Cited by 279 · see citing works

Deletions linked to TP53 loss drive cancer through p53-independent mechanisms

Liu, Y., Chen, C., Xu, Z., Scuoppo, C., Rillahan, C. D., Gao, J., Spitzer, B. G., Bosbach, B., Kastenhuber, E. R., Baslan, T., et al. (2016) · Nature · doi:10.1038/nature17157 · Cited by 272 · see citing works

Significance of immunohistochemistry in breast cancer

Zaha, D. C. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.382 · Cited by 277 · see citing works

Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy

Xiao, Y., Chen, J., Zhou, H., Zeng, X., Ruan, Z., Pu, Z., Jiang, X., Matsui, A., Zhu, L., Amoozgar, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28279-8 · Cited by 267 · see citing works

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230 · see citing works

Somatic TP53 Mutations in the Era of Genome SequencingPreprint

Hainaut, P. L., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 247 · see citing works

p53 and its isoforms in cancer

Bourdon, J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603886 · Cited by 245 · see citing works

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide

Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238 · see citing works

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

Duffy, M. J., Synnott, N. C., & Crown, J. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 234 · see citing works

Targeting mutations in cancer

Waarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 236 · see citing works

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium

Shern, J. F., Selfe, J., Izquierdo, E., Patidar, R., Chou, H.-C., Song, Y., Yohe, M. E., Sindiri, S., Wei, J. S., Wen, X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03060 · Cited by 221 · see citing works

Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods

Chen, J. W., & Dhahbi, J. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-92725-8 · Cited by 208 · see citing works

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma

Swarbrick, A., Woods, S. L., Shaw, A., Balakrishnan, A., Phua, Y. W., Nguyen, A., Chanthery, Y. H., Lim, L., Ashton, L. J., Judson, R. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2227 · Cited by 199 · see citing works

Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells

Yu, Y. H., Yang, L., Zhao, M., Zhu, S., Kang, R., Vernon, P. J., Tang, D., & Cao, L. (2012) · Leukemia · doi:10.1038/leu.2012.65 · Cited by 198 · see citing works

Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections

Tornesello, M. L., Buonaguro, L., Tatangelo, F., Botti, G., Izzo, F., & Buonaguro, L. (2013) · Genomics · doi:10.1016/j.ygeno.2013.04.001 · Cited by 196 · see citing works

Identification of a Cholangiocarcinoma-Like Gene Expression Trait in Hepatocellular Carcinoma

Woo, H. G., Lee, J., Yoon, J., Kim, C. Y., Lee, H., Jang, J. J., Yi, N., Suh, K., Lee, K. U., Park, E. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2823 · Cited by 191 · see citing works

Recent Advances in p53 Research and Cancer Treatment

Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 187 · see citing works

Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium

Goebell, P. J., & Knowles, M. A. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.04.003 · Cited by 178 · see citing works

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types

Sampson, J. N., Wheeler, W. A., Yeager, M., Panagiotou, O. A., Wang, Z., Berndt, S. I., Qing Lan, B., Abnet, C. C., Amundadottir, L. T., Figueroa, J. D., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv279 · Cited by 181 · see citing works

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

Xu-Monette, Z. Y., Medeiros, L. J., Li, Y., Orlowski, R. Z., Andreeff, M., Bueso-Ramos, C., Greiner, T. C., McDonnell, T. J., & Young, K. H. (2012) · Blood · doi:10.1182/blood-2011-11-366062 · Cited by 179 · see citing works

Mutational spectra of human cancer

Pfeifer, G. P., & Nia, A. B. (2009) · Human Genetics · doi:10.1007/s00439-009-0657-2 · Cited by 177 · see citing works

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166 · see citing works

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death &amp; Disease · doi:10.1038/cddis.2013.417 · Cited by 170 · see citing works

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution

Hou, H.-A., Chou, W.-C., Kuo, Y.-Y., Liu, C.-Y., Lin, L., Tseng, M.-H., Chiang, Y.-C., Liu, M.-C., Liu, C.-W., Tang, J.-L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.59 · Cited by 165 · see citing works

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163 · see citing works

The role of DNA damage responses in p53 biology

Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 165 · see citing works

The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute

de Andrade, K. C., Lee, E. E., Tookmanian, E. M., Kesserwan, C. A., Manfredi, J. J., Hatton, J. N., Loukissas, J. K., Zavadil, J., Zhou, L. J., Olivier, M., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00976-3 · Cited by 162 · see citing works

Recent advances in p53 research: an interdisciplinary perspective

Olivier, M., Petitjean, A., Marcel, V., Pétré, A., Mounawar, M., Plymoth, A., de Fromentel, C. C., & Hainaut, P. L. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.69 · Cited by 161 · see citing works

TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies

Klug, S. J., Ressing, M., Koenig, J., Abba, M. C., Αγοραστός, Θ., Brenna, S. M. F., Ciotti, M., Das, B., Mistro, A. D., Dybikowska, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70187-1 · Cited by 158 · see citing works

Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues

Krimmel‐Morrison, J. D., Schmitt, M. W., Harrell, M. I., Agnew, K. J., Kennedy, S. R., Emond, M. J., Loeb, L. A., Swisher, E. M., & Risques, R. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601311113 · Cited by 155 · see citing works

Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors

Levy, C. B., Stumbo, A. C., Bom, A. P. D. A., Portari, E. A., Carneiro, Y., Silva, J. L., & Gallo, C. V. D. M. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.017 · Cited by 150 · see citing works

Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction

Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R. W., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 148 · see citing works

Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer

Naccarati, A., Vymetalkova, V. P., Pardini, B., Vodičková, Ľ., Hemminki, K., Kumar, R., & Vodička, P. (2012) · Mutagenesis · doi:10.1093/mutage/ger067 · Cited by 143 · see citing works

Systematic identification of mutations and copy number alterations associated with cancer patient prognosis

Smith, J. C., & Sheltzer, J. M. (2018) · eLife · doi:10.7554/elife.39217 · Cited by 138 · see citing works

p53 Isoforms and Their Implications in Cancer

Vieler, M., & Sanyal, S. (2018) · Cancers · doi:10.3390/cancers10090288 · Cited by 140 · see citing works

Tumor suppressive role for kinases phosphorylating p53 in DNA damage‐induced apoptosis

Yogosawa, S., & Yoshida, K. (2018) · Cancer Science · doi:10.1111/cas.13792 · Cited by 139 · see citing works

Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53Preprint

Pfister, N. T., & Prives, C. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026054 · Cited by 139 · see citing works

Early onset HER2‐positive breast cancer is associated with germline TP53 mutations

Melhem‐Bertrandt, A., Bojadzieva, J., Ready, K. J., Obeid, E. I., Liu, D. D., Gutierrez‐Barrera, A. M., Litton, J. K., Olopade, O. I., Hortobágyi, G. N., Strong, L. C., et al. (2011) · Cancer · doi:10.1002/cncr.26377 · Cited by 137 · see citing works

TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma

Perrone, F., Bossi, P., Cortelazzi, B., Locati, L. D., Quattrone, P., Pierotti, M. A., Pilotti, S., & Licitra, L. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4170 · Cited by 137 · see citing works

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)

Tan, B. S., Tiong, K. H., Choo, H. L., Chung, F. F., Hii, L., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.191 · Cited by 137 · see citing works

Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.137 · Cited by 134 · see citing works

Mevalonate Pathway and Human Cancers

Tamanoi, F., Azizian, M., Ashrafi, M., & Bathaie, S. Z. (2016) · Current Molecular Pharmacology · doi:10.2174/1874467209666160112123205 · Cited by 132 · see citing works

TP53mutations, expression and interaction networks in human cancers

Wang, X., & Sun, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.13483 · Cited by 132 · see citing works

Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer

Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J., Miotke, L. K., Hopmans, E. S., Xu, H., Pai, R. K., Palm, C., Regan, J. F., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0428-9 · Cited by 126 · see citing works

What is pH regulation, and why do cancer cells need it?

Swietach, P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-09778-x · Cited by 128 · see citing works

The impact of p53 and p73 on aneuploidy and cancer

Tomasini, R., Mak, T. W., & Melino, G. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.03.003 · Cited by 126 · see citing works

DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset

Berg, M., Danielsen, S. A., Ahlquist, T. C., Merok, M. A., Ågesen, T. H., Vatn, M. H., Mala, T., Sjo, O. H., Bakka, A. O., Moberg, I. O., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013978 · Cited by 125 · see citing works

Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression

Wang, W., Cheng, B., Miao, L., Mei, Y., & Wu, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.97 · Cited by 124 · see citing works

Silver nanoparticles defeat p53-positive and p53-negative osteosarcoma cells by triggering mitochondrial stress and apoptosis

Kovács, D., Igaz, N., Keskeny, C., Bélteky, P., Tóth, T., Gáspár, R., Madarász, D., Rázga, Z., Kónya, Z., Boros, I., et al. (2016) · Scientific Reports · doi:10.1038/srep27902 · Cited by 124 · see citing works

Activation of Lung p53 by Nutlin-3a Prevents and Reverses Experimental Pulmonary Hypertension

Mouraret, N., Marcos, É., Abid, S., Gary‐Bobo, G., Saker, M., Houssaini, A., Dubois‐Randé, J., Boyer, L., Boczkowski, J., Dérumeaux, G., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002434 · Cited by 124 · see citing works

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study

Hanna, G. J., Busaidy, N. L., Chau, N. G., Wirth, L. J., Barletta, J. A., Calles, A., Haddad, R. I., Kraft, S., Cabanillas, M. E., Rabinowits, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2297 · Cited by 123 · see citing works

MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity

Xue, J., Chi, Y., Chen, Y., Huang, S., Ye, X., Niu, J., Wang, W., Pfeffer, L. M., Shao, Z.-M., Wu, Z.-H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.96 · Cited by 121 · see citing works

Kaposi’s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies

Ruocco, E., Ruocco, V., Tornesello, M. L., Gambardella, A., Wolf, R., & Buonaguro, L. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2013.01.008 · Cited by 121 · see citing works

Immunohistochemical correlates of TP53 somatic mutations in cancer

Murnyák, B., & Hortobágyi, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11912 · Cited by 116 · see citing works

A TP53 -associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma

Xu, F., Lin, H., He, P., He, L., Chen, J., Lin, L., & Chen, Y. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731943 · Cited by 114 · see citing works

Targeting the Checkpoint to Kill Cancer Cells

Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 110 · see citing works

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

Bourdon, J., Khoury, M. P., Diot, A., Baker, L., Fernandes, K., Aoubala, M., Quinlan, P., Purdie, C. A., Jordan, L. B., Prats, A., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2811 · Cited by 110 · see citing works

Translation acrobatics: how cancer cells exploit alternate modes of translational initiation

Sriram, A., Bohlen, J., & Teleman, A. A. (2018) · EMBO Reports · doi:10.15252/embr.201845947 · Cited by 110 · see citing works

Epigenetic Regulation of Multiple Tumor-Related Genes Leads to Suppression of Breast Tumorigenesis by Dietary Genistein

Li, Y., Chen, H., Hardy, T. M., & Tollefsbol, T. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054369 · Cited by 109 · see citing works

Widespread parainflammation in human cancer

Aran, D., Lasry, A., Zinger, A., Biton, M., Pikarsky, E., Hellman, A., Butte, A. J., & Ben‐Neriah, Y. (2016) · Genome biology · doi:10.1186/s13059-016-0995-z · Cited by 104 · see citing works

WEE1 Inhibitor: Clinical Development

Kong, A. H., & Mehanna, H. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01098-8 · Cited by 108 · see citing works

A comparison between p53 accumulation determined by immunohistochemistry andTP53mutations as prognostic variables in tumours from breast cancer patients

Alsner, J., Jensen, V., Kyndi, M., Offersen, B. V., Vu, P., Børresen‐Dale, A., & Overgaard, J. (2008) · Acta Oncologica · doi:10.1080/02841860802047411 · Cited by 107 · see citing works

Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome

Palmero, E. I., Achatz, M. I., Ashton‐Prolla, P., Olivier, M., & Hainaut, P. L. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333bf00 · Cited by 105 · see citing works

Targeting prostate cancer based on signal transduction and cell cycle pathways

Lee, J. T., Lehmann, B. D., Terrian, D. M., Chappell, W. H., Stivala, F., Libra, M., Martelli, A. M., Steelman, L. S., & McCubrey, J. A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6166 · Cited by 104 · see citing works

Alterations of theTP53Gene in Gastric and Esophageal Carcinogenesis

Bellini, M. F., Cadamuro, A. C. T., Succi, M., Proença, M. A., & Silva, A. E. (2012) · BioMed Research International · doi:10.1155/2012/891961 · Cited by 104 · see citing works

Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53

Jordan, J. J., Menendez, D., Inga, A., Nourredine, M., Bell, D., & Resnick, M. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000104 · Cited by 103 · see citing works

Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide

Wang, X., Chen, J., Liu, J., You, C., Liu, Y., & Mao, Q. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3380-0 · Cited by 103 · see citing works

Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium

Mai, P. L., Malkin, D. M., Garber, J. E., Schiffman, J. D., Weitzel, J. N., Strong, L. C., Wyss, O., Locke, L., Means, V., Achatz, M. I., et al. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.06.008 · Cited by 103 · see citing works

Deep Learning-Driven Lung Cancer Detection: Integrating Image Processing and Web-Based Visualization

Nisha, J. R., Abedin, M. J., Nahyan, N., Faruk, R., Hridi, T. E. F., & Ahammed, M. T. (2025) · IEEE International Conference on Quantum Photonics, Artificial Intelligence & Networking (QPAIN) · doi:10.1109/qpain66474.2025.11171755 · Cited by 103 · see citing works

TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

Li, V. D., Li, K. H. L., & Li, J. T. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2817-z · Cited by 99 · see citing works

Impact of mutant p53 functional properties on <i>TP53</i> mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · see citing works

TP53 Mutations in Human Cancers: Selection versus Mutagenesis

Olivier, M., Petitjean, A., de Fromentel, C. C., & Hainaut, P. L. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_1 · Cited by 6 · see citing works

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

Monti, P., Menichini, P., Speciale, A., Cutrona, G., Fais, F., Taìana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593383 · Cited by 92 · see citing works

TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

Li, V. D., Li, K. H. L., & Li, J. T. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2817-z · Cited by 99 · see citing works

The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers

Olivier, M., Hainaut, P. L., & Petitjean, A. (2007) · IATREIA